Brief: Gensight Biologics Announces Positive Data For PIONEER Phase I/II Trial Of GS030

Gensight Biologics SA

14/04/2020 06:57

April 14 (Reuters) - GENSIGHT BIOLOGICS SA  SIGHT.PA :
    * ANNOUNCES POSITIVE DATA SAFETY MONITORING BOARD REVIEW OF
PIONEER PHASE I/II TRIAL OF GS030 COMBINING GENE THERAPY AND
OPTOGENETICS FOR TREATMENT OF RETINITIS PIGMENTOSA
    * EXPECTS TO COMPLETE ENROLLMENT IN SECOND HALF OF 2020
    * EARLY FINDINGS FROM FIRST TWO COHORTS MAY BE AVAILABLE IN
COURSE
OF 2020
    * TO DELAY RECRUITING NEW PATIENTS INTO THE THIRD COHORT
UNTIL THE
PUBLIC HEALTH SITUATION HAS IMPROVED

Source text for Eikon:  ID:nBwrnHVra 
Further company coverage:  SIGHT.PA 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))